An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Primary, Elective, Open, Abdominal Hysterectomy.

Trial Profile

An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Undergoing Primary, Elective, Open, Abdominal Hysterectomy.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2012 Company (Takeda Global Research and Development Center) added as trial sponsor as reported by ClinicalTrials.gov.
    • 21 Apr 2012 Planned number of patients changed from 224 to 230 as reported by EudraCT.
    • 17 Jun 2010 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top